Tolmar is a specialty pharmaceutical company developing long-acting injectable therapies in urology, oncology and endocrinology, available in 68 countries.
Tolmar is a specialty pharmaceutical company founded in 2007 that develops and delivers long-acting injectable therapies in urology, oncology and endocrinology. Its products and services are available in 68 countries.
The company operates a vertically integrated model spanning research and development, polymer development, pharmaceutical manufacturing and commercialization. This approach underpins its portfolio, including the first six-month LHRH injectable treatment. Tolmar's technical work centres on long-acting injectable drug delivery and polymer development.
Alongside its therapies, Tolmar provides patient support services comprising educational resources, patient assistance programmes and community engagement for healthcare providers and patients. The company extends its reach through strategic partnerships.
Tolmar describes its culture as one that is not satisfied with the status quo and is motivated to discover, transform and forge new paths toward advanced patient care and experience, with an emphasis on quality control and innovation.
